Androgen deprivation therapy (ADT) remains a cornerstone of the management of prostate cancer. The addition of ADT to radiotherapy improves disease-free and overall survival in the locally advanced setting and ADT forms the backbone onto which additional treatments may be added (either initially at first presentation or sequentially at disease progression). ADT is most commonly achieved with Gonadotrophin Releasing Hormone analogues (GnRHa) that act through the hypothalamic-pituitary-gonadal axis to prevent testicular production of testosterone. However, the therapeutic benefits of ADT are partially offset by its side-effects which include long-term This article is protected by copyright. All rights reserved.
BJU international. 2018 Feb 01 [Epub ahead of print]
Duncan C Gilbert, Trinh Duong, Matthew Sydes, Anna Bara, Noel Clarke, Paul Abel, Nick James, Ruth Langley, Max Parmar, STAMPEDE and PATCH Trial Management Groups
MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, 90 High Holborn, London, WC1V 6LJ., Department of Urology, Christie and Salford Royal NHS Foundation Trusts, Manchester, UK., 3N Dept of Urology, Imperial College, Charing Cross Campus, Fulham Palace Road, London, W6 8RF., Institute of Cancer and Genomic Sciences, University of Birmingham, Edgbaston, Birmingham, B15 2TT.